On November 13, 2025, CF PharmTech, Inc. (2652) announced that the Board of Directors approved a resolution to grant a general mandate for repurchase of its issued H shares listed on the Main Board of The Stock Exchange of Hong Kong. The proposal is scheduled to be submitted for shareholder consideration and approval at an extraordinary general meeting.
The announcement indicates that an explanatory statement, as required by the relevant listing rules, will be included in the circular for the upcoming meeting. The statement aims to provide shareholders with adequate information to make an informed decision regarding the proposed share repurchase mandate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.